Targeting the Tyrosine Kinase 2 (TYK2) Pseudokinase Domain: Discovery of the Selective TYK2 Inhibitor ABBV-712
E Breinlinger, S Van Epps, M Friedman… - Journal of Medicinal …, 2023 - ACS Publications
Tyrosine kinase 2 (TYK2) is a nonreceptor tyrosine kinase that belongs to the JAK family
also comprising JAK1, JAK2, and JAK3. TYK2 is an attractive target for various autoimmune …
also comprising JAK1, JAK2, and JAK3. TYK2 is an attractive target for various autoimmune …
[HTML][HTML] Machine learning based prediction of COVID-19 mortality suggests repositioning of anticancer drug for treating severe cases
Despite available vaccinations COVID-19 case numbers around the world are still growing,
and effective medications against severe cases are lacking. In this work, we developed a …
and effective medications against severe cases are lacking. In this work, we developed a …
[HTML][HTML] Potent and selective knockdown of tyrosine kinase 2 by antisense oligonucleotides
NV Tran, LTA Nguyen, KW Lim, AT Phan - Immunohorizons, 2021 - journals.aai.org
Abstract Tyrosine kinase 2 (TYK2) is a member of the JAK family of nonreceptor tyrosine
kinase, together with JAK1, JAK2, and JAK3. JAKs are important signaling mediators of …
kinase, together with JAK1, JAK2, and JAK3. JAKs are important signaling mediators of …
A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation-and autoimmune-related pathways
CXJ Chen, W Zhang, S Qu, F Xia, Y Zhu… - Cell Communication and …, 2023 - Springer
Background As a member of the Janus kinase (JAK) family, which includes JAK1, JAK2 and
JAK3, tyrosine kinase 2 (TYK2) plays an important role in signal transduction and immune …
JAK3, tyrosine kinase 2 (TYK2) plays an important role in signal transduction and immune …
The evolution in our understanding of the genetics of rheumatoid arthritis and the impact on novel drug discovery
Introduction: Rheumatoid arthritis (RA) is an autoimmune disease that is characterized by
chronic inflammation of the joints and affects 1% of the population. Polymorphisms of genes …
chronic inflammation of the joints and affects 1% of the population. Polymorphisms of genes …
Efficient synthesis of tert-butyl 3-cyano-3-cyclopropyl-2-oxopyrrolidine-4-carboxylates: Highly functionalized 2-pyrrolidinone enabling access to novel macrocyclic …
Y Sasaki, H Tokuhara, Y Ohba, A Okabe… - Bioorganic & Medicinal …, 2020 - Elsevier
Herein we report an efficient method for the synthesis of a highly functionalized 2-
pyrrolidinone, tert-butyl 3-cyano-3-cyclopropyl-2-oxopyrrolidine-4-carboxylate, from readily …
pyrrolidinone, tert-butyl 3-cyano-3-cyclopropyl-2-oxopyrrolidine-4-carboxylate, from readily …
Identifying RNA biomarkers and molecular pathways involved in multiple subtypes of uveitis
JT Rosenbaum, CA Harrington, RP Searles… - American journal of …, 2021 - Elsevier
Purpose Uveitis is a heterogeneous collection of diseases. We tested the hypothesis that
despite the diversity of uveitides, there could be common mechanisms shared by multiple …
despite the diversity of uveitides, there could be common mechanisms shared by multiple …
Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan
T Hagino, H Saeki, E Fujimoto… - Journal of Dermatological …, 2024 - Taylor & Francis
Background Deucravacitinib is a selective oral tyrosine kinase 2 (TYK2) inhibitor recently
approved for psoriasis. Objectives We aimed to evaluate the real-world effectiveness and …
approved for psoriasis. Objectives We aimed to evaluate the real-world effectiveness and …
Demonstration of In Vitro to In Vivo Translation of a TYK2 Inhibitor That Shows Cross Species Potency Differences
BS Gerstenberger, ME Banker, JD Clark, ME Dowty… - Scientific Reports, 2020 - nature.com
Translation of modulation of drug target activity to therapeutic effect is a critical aspect for all
drug discovery programs. In this work we describe the profiling of a non-receptor tyrosine …
drug discovery programs. In this work we describe the profiling of a non-receptor tyrosine …
Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease
OH Nielsen, TL Boye, D Chakravarti… - Trends in Pharmacological …, 2022 - cell.com
Recent significant advances have been made in the treatment of chronic inflammatory
diseases with initiation of the era of biologics. However, an unmet medical need still exists …
diseases with initiation of the era of biologics. However, an unmet medical need still exists …